Smithbridge Asset Management Inc. DE has significantly increased its stake in Apollo Global Management Inc. (NYSE:APO) by 37% in the fourth quarter, now holding 133,565 shares valued at $19.3 million. Apollo is gaining attention for its involvement in the AI infrastructure boom, including a $35 billion capital solution for Broadcom and backing Anthropic’s expansion. Analysts generally maintain a "Moderate Buy" rating for Apollo, with an average price target of $151.23, and the company recently beat EPS estimates and raised its dividend.

JPMorgan Chase & Co. has issued $5 million in callable fixed-rate notes due June 11, 2036, offering an annual interest rate of 5.25%. The notes are callable semi-annually by JPMorgan starting June 11, 2031, and maturing on June 11, 2036. The offering highlights key risks including the issuer's right to early redemption, credit risk of JPMorgan Chase & Co., and the notes not being FDIC-insured.

News Corp has announced ongoing repurchases under its US$1 billion authorized 2025 repurchase program, having bought approximately US$298.8 million worth of shares to date. On June 10, 2026, the company repurchased 7,677,609 shares for US$192,243,433.50, with additional purchases across other classes that same day. These repurchases are aimed at enhancing shareholder value, with timing and amounts subject to market conditions.

Wolfe Research has increased its Q1 2028 EPS estimates for Dollar General (NYSE:DG) to $2.21, up from $2.13, and maintained an "Outperform" rating with a $165.00 price target. This upgrade comes amidst mixed analyst sentiment as several other firms recently lowered their price targets and maintained "Hold" or "Neutral" ratings. Dollar General recently reported Q1 earnings of $2.00 EPS, beating consensus estimates, and declared a quarterly dividend of $0.59.

Erste Group Bank has raised its FY2027 earnings per share forecast for TJX Companies to $5.20, up from $5.09, with a FY2028 estimate of $5.75 EPS. This positive revision follows TJX Companies reporting strong quarterly earnings, surpassing analyst expectations with $1.19 EPS and $14.32 billion in revenue. Several other brokerages have also reiterated "buy" ratings and increased price targets for the apparel and home fashions retailer.

Erste Group Bank has reduced its FY2027 earnings per share estimate for Verizon Communications (NYSE: VZ) to $5.24, down from $5.25, and maintains a "Hold" rating. Despite this, Verizon's stock has seen a 2.6% increase, and other analysts have given varying price targets and ratings, with a consensus of "Moderate Buy" and a target price of $50.59. The company also recently announced a quarterly dividend of $0.7075 per share, representing an annualized dividend of $2.83 and a yield of 6.0%.

Nixon Capital LLC has disclosed a new stake in Mid-America Apartment Communities (NYSE:MAA), purchasing 144,034 shares valued at approximately $20 million, making it about 5.3% of their portfolio. The REIT recently reported strong Q1 earnings per share of $2.13, significantly exceeding analyst expectations, and declared a quarterly dividend of $1.53 per share. Analysts generally rate the stock as "Hold" with a consensus price target of $144.19.

Takeda's experimental autoimmune drug, zasocitinib, outperformed Bristol Myers Squibb's Sotyktu in a head-to-head study for psoriasis, demonstrating statistical superiority in efficacy. Zasocitinib completely cleared skin lesions in over a third of recipients, significantly more than Sotyktu. These results support Takeda's confidence in zasocitinib's commercial potential in a competitive market for oral autoimmune treatments.

Takeda Pharmaceutical announced that its experimental AI-developed psoriasis pill, zasocitinib, demonstrated superior efficacy compared to Bristol Myers Squibb's Sotyktu in a late-stage clinical trial. Zasocitinib achieved greater skin clearance and showed a consistent safety profile, positioning it as a potential blockbuster drug that could generate annual sales of $3 billion to $6 billion, helping to offset revenue losses from an upcoming patent cliff for another Takeda drug. The company plans to seek FDA approval for zasocitinib this fiscal year.

Kimco Realty's operating subsidiary has priced an offering of $525 million in 3.50% exchangeable senior notes due 2031, with an option for initial purchasers to acquire an additional $75 million. The retail REIT plans to use a portion of the net proceeds to repurchase shares and the remainder for general corporate purposes, including debt reduction and acquisition opportunities. This follows Kimco Realty's strong Q1 2026 earnings, which surpassed analyst expectations.